Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Pseudohypoparathyroidism: early-phase trial registry

1 of 3 indexed Pseudohypoparathyroidism trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Pseudohypoparathyroidism: 3 US clinical trials tracked, 1 recruiting.

Pseudohypoparathyroidism is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Vanderbilt University Medical Center, running 2 of these trials.

Enrollment posture brief

Registry condition pseudohypoparathyroidism

OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Pseudohypoparathyroidism (th…33%
Open-enrollment share among volume-matched conditions near Pseudohypoparathyroidism

Pseudohypoparathyroidism lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pseudohypoparathyroidism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pseudohypoparathyroidism is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 22

Phase Distribution

PhaseTrial count
Phase 2 2

Named interventions

Most-linked intervention names on Pseudohypoparathyroidism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Theophylline Drug
2 trials
Placebos Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Pseudohypoparathyroidism trials. A trial with sites in several states counts in each.

Tennessee 2 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pseudohypoparathyroidism page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pseudohypoparathyroidism condition card totals 3 registered trials; most-linked intervention Theophylline; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.